Daiichi Sankyo Company, Limited

Daiichi Pharmaceutical Co., Ltd.

Tohto Kasei Co., Ltd.

Yasuyuki Takeda

Kenji Yoshikawa

Yuko Yamamoto

Yoshiko Kagoshima

Yuichi Tominaga

Yoshito Hamada

Ryoichi Tanaka

Shuya Shinohara

Masaki Kiga

Nobuhisa Saitoh

Masayoshi Hanafusa

Hidenori Nozawa

Makoto Takemura

Hisashi Takahashi

Rie Miyauchi

Satoshi Komoriya

Hidekazu Inoue

Tsunehiko Soga

Kouichi Uoto

Shuichi Yokohama

Hidenobu Murafuji

Junichi Kuroyanagi

Kazuo Kanai

Bitoku Takahashi

Satoshi Muneoka

Rie Inaba

Toshiharu Noji

Yamato Suzuki

Keiichi Kawagoe

Yoshihiro Yokomizo

Aki Yokomizo

Cystic fibrosis is developed through mutation of Cystic Fibrosis Transmembrane conductance Regulator (CFTR), which is one type of chloride channel. An object of the present invention is to provide compounds effective in the treatment of cystic fibrosis that open a chloride channel different from CFTR, which is the cause of the disease, and do not depend on CFTR. Compounds of the present invention are compounds or pharmaceutically acceptable salts thereof that open calcium dependent chloride channels (CaCCs) via G-protein coupled receptor 39 (GPR39) agonism to have strong chloride ion-secretory action, and are represented by the following general formula (I): General formula (I): wherein,

Pyrimidine derivative

The present invention is intended to provide a compound or a pharmacologically acceptable salt thereof which is useful in the treatment of a tumor through its ROS1 kinase enzyme activity inhibitory effect and NTRK kinase enzyme inhibitory effect. The present invention provides a compound having an imidazo[1,2-b]pyridazine structure represented by the general formula (I) or a pharmacologically acceptable salt thereof, and a pharmaceutical composition comprising the compound. In the formula, R, G, T, Y, Y, Y, and Yare as defined herein.

Imidazo[1,2-b]pyridazine derivatives as kinase inhibitors

The present invention provides a method for effectively producing an optically active form of tetrasubstituted-5-azaspiro[2.4]heptane derivative, which serves as a useful production intermediate for quinolonecarboxylic acid antibacterial agents, and intermediates for the derivative. The present invention is directed to a method for producing a compound (VII) according to the following scheme. 

Process for preparation of tetrasubstituted 5-azaspiro[2.4]- heptane derivatives and optically active intermediates thereof

This invention is to provide a novel taxol derivative useful as an antitumor compound having respective substituent groups, represented by the following formula (I) which can be orally administered

Pentacyclic taxan compound

A modified phenolic hydroxyl-containing resin having a low free difunctional phenol content and represented by general formula (1); a solid epoxy resin having an epoxy equivalent of 450 to 2,500 g/eq and prepared by epoxidizing the above resin; and another solid epoxy resin having an epoxy equivalent of 1,500 to 60,000 g/eq and a number-average molecular weight of 3,000 to 15,000 and prepared by reacting the above epoxy resin with a difunctional phenol compound. Resin compositions containing these resins have many applications as powder coatings and can paints. In formula (1), X represents a residue of a difunctional phenol compounds; X's may be the same or different; and n is the number of repeating units and is an integer of 0 or above.

Modified phenolic hydroxyl-containing resin by reacting epoxy resin with difunctional phenol

Phenolic hydroxyl-containing resin by reacting epoxy resin with excess

Aminophenol derivatives

Growing community of inventors

Edogawa-ku, Japan

Yasuyuki Takeda